SCHEMBL7609447

SCHEMBL7609447

CCC(C(=O)O)c1c(NP(=O)(O)Cc2ccccc2)ccc2ccccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
GAA P10253 2/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
GPR55 Q9Y2T6 1/20 0.35
KDM4E B2RXH2 4/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
PPARG P37231 2/20 0.34
PPARA Q07869 1/20 0.34
GSK3B P49841 1/20 0.34
ELANE P08246 3/20 0.34
CA12 O43570 1/20 0.33
CA2 P00918 1/20 0.33
MMP2 P08253 1/20 0.33
MMP9 P14780 1/20 0.33
MMP8 P22894 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7609434 0.91 MEN1 (0.37) ACP3ALDH1A1MEN1KMT2AGAA
SCHEMBL7606879 0.89 CNR2 (0.36) ALDH1A1MEN1KMT2AGAANPSR1
SCHEMBL7607490 0.86 AKR1B1 (0.39) ACP3ALDH1A1MEN1KMT2AGAA
SCHEMBL7611156 0.77 HTT (0.39) ACP3ALDH1A1MEN1KMT2AGAA
SCHEMBL7604500 0.76 ALOX5 (0.39) ALDH1A1MEN1KMT2AGAANPSR1
SCHEMBL7604642 0.76 KDM4E (0.51) ACP3ALDH1A1MEN1KMT2AGAA
SCHEMBL7614727 0.74 KMT2A (0.41) ALDH1A1MEN1KMT2AGAAKDM4E
SCHEMBL7605170 0.73 CYP1A2 (0.41) ACP3ALDH1A1MEN1KMT2AGAA
SCHEMBL7606184 0.73 ALDH1A1 (0.41) ALDH1A1MEN1KMT2AKDM4ELMNA
SCHEMBL7606135 0.70 ANPEP (0.35) ALDH1A1KDM4EHPGDPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2002515040-A 2002-05-21 JP claimed
JP-2002514160-A 2002-05-14 JP claimed
EP-0954295-A1 METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1999-11-10 EP claimed
EP-0936914-A1 HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1999-08-25 EP claimed
EP-0936914-A4 1999-08-25 EP claimed
WO-1997048400-A1 HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1997-12-24 WO claimed
WO-1997048409-A1 METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1997-12-24 WO claimed
EP-1044206-A1 PRODRUGS OF NAALADASE INHIBITORS Guildford Pharmaceuticals Inc. (US) 2000-10-18 EP disclosed
EP-1005348-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 2000-06-07 EP disclosed
US-6046180-A NAALADase inhibitors GUILFORD PHARMACEUTICALS INC. (US) 2000-04-04 US disclosed
EP-0954295-A1 METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1999-11-10 EP disclosed
WO-1999033849-A1 PRODRUGS OF NAALADASE INHIBITORS GUILDFORD PHARMACEUTICALS INC. (US) 1999-07-08 WO disclosed
WO-1998013046-A1 NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 WO disclosed
WO-1997048409-A1 METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1997-12-24 WO disclosed